Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Other Non-Current Liabilities (2016 - 2025)

Anaptysbio (ANAB) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $276.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 21.76% year-over-year to $276.5 million, compared with a TTM value of $276.5 million through Dec 2025, down 21.76%, and an annual FY2025 reading of $276.5 million, down 21.76% over the prior year.
  • Other Non-Current Liabilities was $276.5 million for Q4 2025 at Anaptysbio, down from $331.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $362.0 million in Q2 2024 and bottomed at $35.0 million in Q3 2022.
  • Average Other Non-Current Liabilities over 5 years is $293.7 million, with a median of $310.2 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 789.35% in 2023, then fell 21.76% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $251.1 million in 2021, then increased by 21.24% to $304.4 million in 2022, then increased by 2.1% to $310.8 million in 2023, then rose by 13.71% to $353.4 million in 2024, then fell by 21.76% to $276.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ANAB at $276.5 million in Q4 2025, $331.8 million in Q3 2025, and $331.4 million in Q2 2025.